Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affinity Life Sciences, a contract manufacturing company and JSW Life Sciences, a full service contract research organisation, have entered into a strategic partnership to enhance contract research and manufacturing capabilities for the pharmaceutical industry, medical devices, biotechnology, and as well as governmental and academic agencies.
Subscribe to our email newsletter
Both Affinity and JSW are expected to continue to offer their products and services under strict quality control measurements which meet government and regulatory requirements such as FDA, EMEA, ISO and OECED, including GLP/GMP/GxP standards. Each company will continue to operate as independent entities while still having access to the core strengths of each company.
Tod Gavron, president of Affinity Life Sciences, said: “This is another important step for Affinity as we continue to strengthen our service offerings. Affinity can now offer its clients expanded drug development services for neurodegenerative diseases from a truly respected and trusted institution like JSW. JSW’s expertise as a CRO and its worldwide network will provide clients with an increased knowledge base, global reach, and capacity allowing for even greater flexibility when tackling custom projects.”
Manfred Windisch, president of JSW, said: “The synergy between JSW and Affinity Life Sciences provides our customers with additional biomarker assay development and GMP production services in support of drug development studies. This partnership will allow JSW to further serve our North American and European clients with a strong, established company in Affinity.”